Simplify Logo
Sobi

Sobi

Develops therapies for rare diseases

Medical Science Liaison - Hematology

Full-Time
$180k - $215k/yr

+ Short-term bonus + Long-term bonus + 401(k) match + Tuition reimbursement + Wellness reimbursement + Recognition awards

Junior
PharmD, PhD, MD
San Jose, CA, USA
Remote

Frequent travel of 60% or more is required within the Northern California territory.

About the job

Requirements
  • An accredited doctorate degree in a life-science or basic-science discipline, such as a Pharm.D., D.Sc., D.N.P., Ph.D., or M.D./D.O.; candidates with an advanced health-related degree combined with extensive industry or clinical experience will also be considered.
  • At least 1 year of Medical Science Liaison experience in hematology/oncology and rare disease.
  • Existing familiarity with the Northern California medical and scientific community and key institutions.
  • Ability to understand and effectively communicate scientific information, respond to inquiries, and address the needs of key stakeholders.
  • Strong written and oral communication skills, with the ability to shape and articulate a clear strategy and narrative.
  • Demonstrated success managing internal and external stakeholders and leading or influencing cross-functional teams in a matrixed environment.
  • Ability to prioritize and manage multiple projects concurrently.
  • A proven track record of strategic thinking, problem-solving, and decision-making.
  • Ability to initiate and maintain relationships throughout the medical community.
  • Demonstrated ability to build positive, constructive relationships with cross-functional internal team members.
  • Understanding of the highly regulated biopharmaceutical industry environment, including basic knowledge of the legal and regulatory landscape.
Responsibilities
  • Serve as the primary field-based point of contact for Sobi Medical Affairs within the Northern California territory.
  • Engage with key thought leaders and healthcare professionals to exchange scientific information accurately, fairly, and in a balanced manner.
  • Report field intelligence to Sobi, including competitive insights, perspectives on compounds, disease states, and the treatment landscape.
  • Support clinical development and operations teams through site recommendations, site initiation visits, communication facilitation, and accrual support activities.
  • Participate in and sometimes lead advisory board meetings at the local, regional, and national levels.
  • Deliver internal and external training on preclinical science, clinical data, and outcomes.
  • Represent Sobi at medical conferences and provide session summaries.
  • Serve as a cross-functional scientific resource across the organization in accordance with company guidelines.
  • Maintain advanced, current knowledge of relevant studies, compounds, and disease states to support scientific discussions with hematology/oncology thought leaders.
  • Manage the assigned Northern California territory while contributing to the success of colleagues and the broader Medical Science Liaison organization.

About the company

Sobi specializes in developing and delivering therapies for rare diseases. It focuses on hematology, immunology, and specialty care, bringing medicines to patients who have limited treatment options. Their products are designed to treat rare conditions and are typically administered by prescription under medical supervision; the company collaborates with partners to advance research, develop, and commercialize these therapies. Sobi differentiates itself through its strong biotechnological foundation from its Biovitrum heritage and a track record of strategic collaborations with major pharmaceutical players like Sanofi and Apellis, which expand its research capabilities and reach. The company’s goal is to improve the lives of patients with rare diseases worldwide by creating and delivering effective treatments that address unmet medical needs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Solna kommun, Sweden

Founded

1988

Get referred to Sobi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue grew 24% CER to SEK 7.184 billion, with 63% strategic portfolio mix.
  • Aspaveli gained EU CE certification in May 2026, expanding self-administration across 12-plus indications.
  • Tryngolza advanced with EMA validation and 85% pancreatitis reduction data, supporting 2027 launch potential.

What critics are saying

  • Guido Oelkers leaves by January 2027, forcing a leadership reset during execution-heavy launches.
  • Tryngolza sHTG faces 2027 approval timing; a rejection kills a major growth driver.
  • Arthrosi, Aspaveli, and Gamifant all depend on regulatory wins; one failure compresses valuation fast.

What makes Sobi unique

  • Sobi covers 90% of rare-disease markets by value, spanning Europe, U.S., and Latin America.
  • Its portfolio mixes launched assets, royalties, and late-stage pipeline programs across hematology and immunology.
  • The 2026 Arthrosi acquisition adds gout depth, strengthening a focused rare-disease commercial platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
Nu Pagamentos S.A. (Nubank)
Aug 7th, 2026
Swedish pharma Sobi acquires full control of Latin American oncology specialist Pint Pharma

Swedish biopharmaceutical company Sobi (Swedish Orphan Biovitrum) is acquiring full ownership of Pint Pharma, a firm specialising in bringing complex treatments, including cancer therapies, to Latin American markets. The transaction builds on Sobi's initial investment last year, when it paid $105 million for most of Pint's economic rights. The deal, submitted to Brazil's competition authority Cade, involves purchasing all remaining shares of Pharma Investments, Pint's parent company. The transaction value remains undisclosed. The acquisition gives Sobi control of a platform operating across seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. Pint handles regulatory approval, market access, and distribution of specialised medicines for rare diseases, haematology, and oncology. Sobi reported revenue of 28.2 billion Swedish kronor (approximately $2.9 billion) in 2025. The companies have maintained a commercial partnership since 2021.

Yahoo Finance
Aug 3rd, 2026
Swedish biopharma Sobi CEO Guido Oelkers to step down by January 2027

Swedish biopharma firm Sobi announced that chief executive Guido Oelkers will step down to take up another position outside the company. Oelkers will continue in his role until the end of January 2027 at the latest. "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team," Oelkers said. He highlighted advancing the pipeline, expanding global footprint, and growing Sobi into a leader in rare diseases. The company will immediately begin searching for a new chief executive. Sobi's operations, strategy, and financial targets remain unchanged, the firm said.

PR Newswire
Jul 15th, 2026
Sobi repurchases shares at $0.05 to secure employee incentive programme commitments

Swedish Orphan Biovitrum (Sobi) is repurchasing shares to support its employee incentive programme. The Board of Directors exercised authorisation granted at the May 2026 Annual General Meeting to repurchase class C shares at approximately SEK 0.55 per share, representing 100% of their quotient value. The repurchase involves 223,677 shares and will occur between 16 July and 6 November 2026. Svenska Handelsbanken will handle the transaction. After converting the repurchased class C shares to common shares, Sobi will hold 10,290,974 own shares. The move secures commitments under the All Employee Programme, a long-term incentive scheme for permanent staff. Sobi, a biopharma company focused on rare diseases, employs approximately 2,000 people globally and reported revenue of SEK 28 billion in 2025.

Associated Press
May 22nd, 2026
Enable Injections' enFuse on-body delivery system receives CE certification for Aspaveli in EU

Enable Injections has received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli (pegcetacoplan), which will be distributed by Swedish Orphan Biovitrum across the European Union as ASPAVELI enFuse. The certification allows caregivers and patients aged 12 and older to use the wearable device for subcutaneous drug administration. The enFuse system delivers medication through a discreet, hands-free device using a small, hidden needle, designed to improve patient self-administration. Aspaveli is approved for treating paroxysmal nocturnal haemoglobinuria, C3G and primary IC-MPGN in patients 12 years and older. This follows recent regulatory clearances in Saudi Arabia, Brazil, South Korea and Canada, part of Enable's strategic partnership with Sobi announced in September 2024.

PR Newswire
May 6th, 2026
Sobi AGM approves $2.7B revenue, elects new board members and long-term incentive programmes

Swedish Orphan Biovitrum (Sobi) held its annual general meeting on 6 May 2026, approving several key resolutions. Shareholders adopted the company's financial statements for 2025 and discharged the board and CEO from liability. David Meek was re-elected as board chair, with Christophe Bourdon, Iris Loew-Friedrich, Staffan Schüberg and Filippa Stenberg re-elected as directors. Mikael Dolsten and Åsa Riisberg joined as new board members. Ernst & Young was re-appointed as auditor. The AGM approved long-term incentive programmes, including an employee programme with up to 223,677 series C shares and a management programme via equity swap. The board received authorisation to issue up to 39,710,000 new shares through various instruments. Sobi reported SEK 28 billion in revenue for 2025.